Abbvie to record $4 billion impairment charges on Stemcentrx assets

Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Original source: http://feeds.reuters.com/~r/reuters/INhealth/~3/3ZPVV_JlqxY/abbvie-to-record-4-billion-impairment-charges-on-stemcentrx-assets-idINKCN1OY212

Related Posts